Chiltern says strategic deals are good for the CRO sector

By Gareth Macdonald

- Last updated on GMT

Related tags: Pharmacology, Big pharma

Chiltern says that strategic partnering in the contract research sector enables CROs to plan for the longer term and is having a tangible impact on brining drugs to market.

Outsourcing-pharma.com spoke with Aize Smink, Chiltern’s senior executive VP, global clinical development, who said that the drug industry’s need for efficiency is driving the formation of such deals.

He explained that these types of collaboration are not limited to Big Pharma, citing the UK-headquartered CROs agreement with a number of mid-sized drug makers as evidence.

“[Strategic partnering] allows us to focus on the long term and look at process improvement in a collaborative way with our pharma partners. So it also drives progress for CROs in that sense​.”

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us

Products

View more

Webinars